Welcome To Diurnal

Diurnal is a UK-based specialty pharmaceutical company dedicated to developing high-quality hormone therapeutics to aid lifelong treatment for rare and chronic endocrine conditions, including Congenital Adrenal Hyperplasia, Adrenal Insufficiency, Hypogonadism and Hypothyroidism.

The company has a strong, multi-skilled entrepreneurial management team with extensive pharmaceutical product development experience and an affiliated network of world-class clinical experts in the area of endocrinology.

Mission Statement

To address the major unmet clinical and patient needs in endocrinology by creating high quality products for the lifelong treatment of chronic conditions.

Latest News

  • 03 Jul
    2019

    Alkindi® Market Authorisation Application Submitted in Australia

    Alkindi® Market Authorisation Application Submitted in Australia

    Read More

  • 28 May
    2019

    Placing, Open Offer and Notice of General Meeting

    Conditional placing of new ordinary shares in the Company and launch of an Open Offer

    Read More

  • 09 May
    2019

    Intent to Submit for Market Authorisation Application for Chronocort® tendered to the EMA

    Diurnal on track to submit Market Authorisation Application in Europe in Q4 2019

    Read More